Drug Profile
Research programme: Alzheimer's disease therapeutics - Evotec SE/Johnson & Johnson Innovative Medicine
Alternative Names: TargetADLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Evotec AG; Janssen Pharmaceuticals
- Developer Evotec SE; Johnson & Johnson Innovative Medicine
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Dec 2017 No recent reports of development identified for research development in Alzheimer's-disease in Germany
- 08 Nov 2013 Early research in Alzheimer's disease in Germany (unspecified route)